(EN) RNA Disruption Assay (RDA)-Breast Cancer Response Evaluation for Individualized Therapy
BREVITY
NCT03524430
 Actif en recrutement
|
CHU DE QUEBEC – UNIVERSITE LAVAL
 HOPITAL DU SAINT-SACREMENT
|
|
Fanie Bourgault
418-525-4444 poste 82697
|
(EN) A Prospective Multi-center Clinical Study Evaluating the Use of PD G 506 A and the Eagle V1.2 Imaging System for the Visualization of Carcinoma During Breast Conserving Surgery
SBI-CIP 20-002
NCT04815083
Actif en recrutement
|
CHU DE QUEBEC – UNIVERSITE LAVAL
HOPITAL DU SAINT-SACREMENT
|
|
Marie-Caude Lépine
418-525-4444 poste 82100
|
(EN) A Phase III, Open-label, Randomised Study of Datopotamab Deruxtecan (Dato-DXd) With or Without Durvalumab Compared With Investigator's Choice of Chemotherapy (Paclitaxel, Nab-paclitaxel or Gemcitabine + Carboplatin) in Combination With Pembrolizumab in Patients With PD-L1 Positive Locally Recurrent Inoperable or Metastatic Triple-negative Breast Cancer
TROPION-Breast05
NCT06103864
Actif en recrutement
|
CHU DE QUEBEC – UNIVERSITE LAVAL
HOPITAL DU SAINT-SACREMENT
|
|
Marie-Caude Lépine
418-525-4444 poste 82100
|
(EN) A Randomized Trial of Five-Fraction Partial Breast Irradiation
RAPID2
NCT05417516
Actif en recrutement
|
CHU DE QUEBEC – UNIVERSITE LAVAL
HOPITAL DE L'ENFANT-JESUS
|
|
Josée Allard
418-525-4444 poste 67296
|
(EN) A Phase III, Open-Label, Randomised Study to Assess the Efficacy and Safety of Camizestrant, a Next Generation, Oral Selective Estrogen Receptor Degrader) vs Standard Endocrine Therapy (Aromatase Inhibitor or Tamoxifen) as Adjuvant Treatment for Patients With ER+/HER2- Early Breast Cancer and an Intermediate-High or High Risk of Recurrence Who Have Completed Definitive Locoregional Treatment and Have No Evidence of Disease
CAMBRIA-2
NCT05952557
Actif en recrutement
|
CHU DE QUEBEC – UNIVERSITE LAVAL
HOPITAL DU SAINT-SACREMENT
|
|
Marie-Caude Lépine
418-525-4444 poste 82100
|
Essai randomisé portant sur la radiothérapie régionale pour le traitement du cancer du sein avec envahissement ganglionnaire à faible risque avec biomarqueur.
MA.39
NCT03488693
Actif en recrutement
|
CHU DE QUEBEC – UNIVERSITE LAVAL
L'HOTEL-DIEU DE QUEBEC ET CRCEO
|
Phase III |
Josée Allard
418-525-4444 poste 16730
|
(EN) A Phase III Clinical Trial Evaluating De-Escalation of Breast Radiation for Conservative Treatment of Stage I, Hormone Sensitive, HER-2 Negative, Oncotype Recurrence Score Less Than or Equal to 18 Breast Cancer
DEBRA
NCT04852887
Actif en recrutement
|
CHU DE QUEBEC – UNIVERSITE LAVAL
HOPITAL DE L'ENFANT-JESUS
|
|
Josée Allard
418-525-4444 poste 67296
|
(EN) Radiation OmisSion in PAtients With CLinically Node Negative Breast Cancer Undergoing Lumpectomy and With a PathologIc Complete REsponse After Neoadjuvant Chemotherapy
ROSALIE
NCT05866458
Actif en recrutement
|
CHU DE QUEBEC – UNIVERSITE LAVAL
HOPITAL DE L'ENFANT-JESUS
|
|
Josée Allard
418-525-4444 poste 67296
|
(EN) A Randomized, Open-Label, Phase 3 Study of Adjuvant Imlunestrant vs Standard Adjuvant Endocrine Therapy in Patients Who Have Previously Received 2 to 5 Years of Adjuvant Endocrine Therapy for ER+, HER2- Early Breast Cancer With an Increased Risk of Recurrence
EMBER-4
NCT05514054
Actif en recrutement
|
CHU DE QUEBEC – UNIVERSITE LAVAL
HOPITAL DU SAINT-SACREMENT
|
|
Fanie Bourgault
418-525-4444 poste 82697
|
(EN) A Phase III, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Efficacy and Safety of Inavolisib in Combination With Phesgo Versus Placebo in Combination With Phesgo As Maintenance Therapy After First Line Induction Therapy in Participants With PIK3CA-Mutated HER2-Positive Locally Advanced or Metastatic Breast Cancer
WO44263 (INAVO122)
NCT05894239
Actif en recrutement
|
CHU DE QUEBEC – UNIVERSITE LAVAL
HOPITAL DU SAINT-SACREMENT
|
|
Fanie Bourgault
418-525-4444 poste 82697
|
Groupe d'étude en oncologie du Québec